Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Awadhesh Kumar Singh. (2015) Polemics of pioglitazone: an appraisal in 2015. Expert Review of Endocrinology & Metabolism 10:4, pages 447-458.
Read now
Read now
Ye-Fong Du, Horng-Yih Ou, Elizabeth A Beverly & Ching-Ju Chiu. (2014) Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clinical Interventions in Aging 9, pages 1963-1980.
Read now
Read now
Xiaoyu Dai, Hongtao Wang, Zhong Jing & Ping Fu. (2014) The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis. Current Medical Research and Opinion 30:9, pages 1777-1786.
Read now
Read now
Abdul Basit, Musarrat Riaz & Asher Fawwad. (2012) Glimepiride: evidence-based facts, trends, and observations. Vascular Health and Risk Management 8, pages 463-472.
Read now
Read now
Thomas Forst, Markolf Hanefeld & Andreas Pfützner. (2011) Review of approved pioglitazone combinations for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:10, pages 1571-1584.
Read now
Read now
James R. Gavin$suffix/text()$suffix/text() & Nancy J. Bohannon. (2010) A Review of the Response to Oral Antidiabetes Agents in Patients with Type 2 Diabetes. Postgraduate Medicine 122:3, pages 43-51.
Read now
Read now
Ángel Rodríguez, Luis Ciprés, Santiago Tofé, Pepa Polavieja & Jesús Reviriego. (2010) Clinical evaluation of combined therapy for type 2 diabetes. Current Medical Research and Opinion 26:5, pages 1171-1183.
Read now
Read now
Vanessa J Briscoe, Michelle L Griffith & Stephen N Davis. (2010) The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Metabolism & Toxicology 6:2, pages 225-235.
Read now
Read now
Giuseppe Derosa & Sibilla AT Salvadeo. (2009) Risk management in the treatment of type 2 diabetes with pioglitazone. Diabetes, Metabolic Syndrome and Obesity 2, pages 51-60.
Read now
Read now
Bo Ahrén. (2008) Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vascular Health and Risk Management 4:2, pages 383-394.
Read now
Read now
John M Stafford & Tom Elasy. (2007) Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vascular Health and Risk Management 3:4, pages 503-510.
Read now
Read now
Articles from other publishers (36)
Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya & Kumar Gaurav. (2023) Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach. International Journal of Diabetes in Developing Countries 43:6, pages 856-874.
Crossref
Crossref
Abhishek Shrivastava, Jothydev Kesavadev, Viswanathan Mohan, Banshi Saboo, Dina Shrestha, Anuj Maheshwari, Brij Mohan Makkar, Kirtikumar D. Modi & Ashok Kumar Das. (2023) Clinical Evidence and Practice-Based Guidelines on the Utility of Basal
Insulin Combined Oral Therapy (Metformin and Glimepiride) in the
Current Era. Current Diabetes Reviews 19:8.
Crossref
Crossref
Yan Peng, Shu‐Hong Chen, Xiao‐Nan Liu & Qing‐Yun Sun. (2018) Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta‐analysis involving eight eligible randomized‐controlled trials. Journal of Cellular Physiology 234:3, pages 2795-2806.
Crossref
Crossref
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, PradeepK Shrestha, Aravinthan Mahalingam, Mazen Askheta, AlyAhmed A. Rahim, Fatimah Eliana, HariK Shrestha, Sandeep Chaudhary, Nancy Ngugi, JeanClaude Mbanya, ThanThan Aye, TintSwe Latt, ZhanayA Akanov, AbbasRaza Syed, Nikhil Tandon, AG Unnikrishnan, SV Madhu, Ali Jawa, Subhankar Chowdhury, Sarita Bajaj & AshokKumar Das. (2018) Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force. Indian Journal of Endocrinology and Metabolism 22:1, pages 132.
Crossref
Crossref
L. M. Neff, M. S. Broder, D. Beenhouwer, E. Chang, E. Papoyan & Z. W. Wang. (2017) Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity. Clinical Obesity 7:6, pages 337-346.
Crossref
Crossref
Niki Katsiki, Nikolaos Tentolouris & Dimitri P. Mikhailidis. (2017) Dyslipidaemia in type 2 diabetes mellitus. Current Opinion in Cardiology 32:4, pages 422-429.
Crossref
Crossref
Yean Yean Soong, Joseph Lim, Lijuan Sun & Christiani Jeyakumar Henry. (2015) Effect of co-ingestion of amino acids with rice on glycaemic and insulinaemic response. British Journal of Nutrition 114:11, pages 1845-1851.
Crossref
Crossref
James H. Flory & Alvin I. Mushlin. (2015) Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement. Journal of Clinical Epidemiology 68:2, pages 200-210.
Crossref
Crossref
M. Monami, S. Genovese & E. Mannucci. (2013) Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 15:10, pages 938-953.
Crossref
Crossref
S.‐C. Liu, Y.‐K. Tu, M.‐N. Chien & K.‐L. Chien. (2012) Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta‐analysis. Diabetes, Obesity and Metabolism 14:9, pages 810-820.
Crossref
Crossref
Lyudmila Alexandrovna Ruyatkina & Maksim Yur'evich Sorokin. (2012) Modern antihyperglycemic therapy: safety and efficacy of glimepiride. Diabetes mellitus 15:2, pages 89-97.
Crossref
Crossref
Nalinee Poolsup, Naeti Suksomboon & Wanwaree Setwiwattanakul. (2012) Efficacy of Various Antidiabetic Agents as Add-On Treatments to Metformin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. ISRN Endocrinology 2012, pages 1-11.
Crossref
Crossref
Dae Young Yoo, Woosuk Kim, Sung Min Nam, Ki-Yeon Yoo, Choong Hyun Lee, Jung Hoon Choi, Moo-Ho Won, In Koo Hwang & Yeo Sung Yoon. (2011) Reduced Cell Proliferation and Neuroblast Differentiation in the Dentate Gyrus of High Fat Diet-Fed Mice are Ameliorated by Metformin and Glimepiride Treatment. Neurochemical Research 36:12, pages 2401-2408.
Crossref
Crossref
A. Avogaro, M. Federici, J. Betteridge, R. Bonadonna, I. W. Campbell, G. H. Schernthaner, B. Staels, E. Farinaro & G. Crepaldi. (2014) Which is the eligible patient to be treated with pioglitazone? The expert view. Journal of Endocrinological Investigation 34:10, pages 781-787.
Crossref
Crossref
Nobuyuki Shihara, Masafumi Kitaoka, Nobuya Inagaki, Takashi Kadowaki, Seisuke Koumoto, Jo Satoh, Yasuo Terauchi, Kiyohide Nunoi, Yuichiro Yamada, Hiroyuki Sakamaki & Yutaka Seino. (2011) Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study. Journal of Diabetes Investigation 2:5, pages 391-398.
Crossref
Crossref
Giuseppe Derosa. (2010) Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus. Drugs 70:15, pages 1945-1961.
Crossref
Crossref
Namyi Gu, Bo-Hyung Kim, HyouYoung Rhim, Jae-Yong Chung, Jung-Ryul Kim, Hyun-Suk Shin, Seo-Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang & Kyung-Sang Yu. (2010) Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clinical Therapeutics 32:7, pages 1408-1418.
Crossref
Crossref
Dan-yan Xu, Shui-Ping Zhao, Qiu-xia Huang, Wei Du, Yu-hua Liu, Ling Liu & Xiao-mei Xie. (2010) Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Research and Clinical Practice 88:1, pages 71-75.
Crossref
Crossref
R. A. DeFronzo, A. H. Stonehouse, J. Han & M. E. Wintle. (2010)
Relationship of baseline HbA
1c
and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
. Diabetic Medicine 27:3, pages 309-317.
Crossref
Crossref
Michael A Nauck & Irfan Vardarli. (2010) Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†. Journal of Diabetes Investigation 1:1-2, pages 24-36.
Crossref
Crossref
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak & Edwin E Salpeter (posthumous). 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jochen Seufert. (2009) The backbone of oral glucose-lowering therapy: time for a paradigm shift?. Fundamental & Clinical Pharmacology 23:6, pages 651-667.
Crossref
Crossref
Stephen C. Bain. (2009) Treatment of Type 2 Diabetes Mellitus With Orally Administered Agents: Advances in Combination Therapy. Endocrine Practice 15:7, pages 750-762.
Crossref
Crossref
G. Bolli, F. Dotta, L. Colin, B. Minic & M. Goodman. (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes, Obesity and Metabolism 11:6, pages 589-595.
Crossref
Crossref
Mark Stolar. (2009) Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. Clinical Medicine. Therapeutics 1, pages CMT.S2370.
Crossref
Crossref
N. PapanasE. Maltezos. (2009) Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. Clinical Medicine. Therapeutics 1, pages CMT.S1085.
Crossref
Crossref
Nicole R Pinelli, Raymond Cha, Morton B Brown & Linda A Jaber. (2008) Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis. Annals of Pharmacotherapy 42:11, pages 1541-1551.
Crossref
Crossref
John HB Scarpello & Harry CS Howlett. (2008) Metformin therapy and clinical uses. Diabetes and Vascular Disease Research 5:3, pages 157-167.
Crossref
Crossref
E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini & N. Marchionni. (2008) Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 0:0, pages 080526191604039-???.
Crossref
Crossref
Matteo Monami, Caterina Lamanna, Niccolò Marchionni & Edoardo Mannucci. (2008) Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice 79:2, pages 196-203.
Crossref
Crossref
A. Macías Batista, I. Peiró Martínez & P.L. de Pablos Velasco. (2008) Terapia combinada. Endocrinología y Nutrición 55, pages 58-65.
Crossref
Crossref
G. Bolli, F. Dotta, E. Rochotte & S. E. Cohen. (2007) Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes, Obesity and Metabolism 0:0, pages 071127144208007-???.
Crossref
Crossref
G. Derosa. (2007) Pioglitazone plus glimepiride: a promising alternative in metabolic control. International Journal of Clinical Practice 61, pages 28-36.
Crossref
Crossref
Emanuele Bosi, Riccardo Paolo Camisasca, Carole Collober, Erika Rochotte & Alan J. Garber. (2007) Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin. Diabetes Care 30:4, pages 890-895.
Crossref
Crossref
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak & Edwin E Salpeter. 1996. The Cochrane Database of Systematic Reviews (Complete Reviews). The Cochrane Database of Systematic Reviews (Complete Reviews).
Emma D Deeks & Lesley J Scott. (2006) Pioglitazone/Metformin. Drugs 66:14, pages 1863-1877.
Crossref
Crossref